Viewing Study NCT00036244



Ignite Creation Date: 2024-05-05 @ 11:25 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00036244
Status: COMPLETED
Last Update Posted: 2005-08-05
First Post: 2002-05-08

Brief Title: Synthetic Human Secretin in Children With Autism
Sponsor: Repligen Corporation
Organization: Repligen Corporation

Study Overview

Official Title: A Phase III Randomized Double-Blind Placebo-Controlled Multiple Dose Study to Assess the Efficacy Safety and Tolerability of RG1068 Synthetic Human Secretin in Children With Autism
Status: COMPLETED
Status Verified Date: 2005-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None